Loading
A phase 1/2 trial of cetuximab, trifluridine/tipiracil and bevacizumab (glioblastoma use) in colorectal cancer, run by Sun Yat-sen University, now recruiting.
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC is a phase 1/2, randomised interventional study registered as NCT07012954 by Sun Yat-sen University, with a registry enrolment figure of 64 participants, started 2025-06-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: Cetuximab (Erbitux, C225); trifluridine/tipiracil; Bevacizumab ( Avastin). Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "* Histologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trifluridine/tipiracil, Bevacizumab (glioblastoma use), Cetuximab, MRD / molecular residual disease testing and the tag colorectal-deep-dive.
Shares Trifluridine/tipiracil, Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Trifluridine/tipiracil, Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Trifluridine/tipiracil, Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Trifluridine/tipiracil, MRD / molecular residual disease testing, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Cetuximab, MRD / molecular residual disease testing, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Cetuximab, Monoclonal antibodies, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/